Tesla owners with 200,000 to 554,000 miles reveal the charging habits that kept their original batteries alive, and one ...
Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.
Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite ...
Bispecific antibodies are highly efficacious and have a milder side effect profile than other late-line treatments for ...
Zacks Investment Research on MSN
Bristol Myers vs Gilead Sciences: Which biotech stock is a better bet now?
Bristol Myers Squibb BMY and Gilead Sciences GILD are two leading biotech players with diversified portfolios and a strong ...
Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne(R) CDx as a ...
MedPage Today on MSN
CAR-T trial raises prospect of preventing myeloma in high-risk group
All 20 smoldering myeloma patients had deep responses after one-time infusion ...
Eli Lilly announced Monday that it is acquiring Kelonia Therapeutics, a developer of gene therapies with a particular focus ...
A deep learning platform may help predict how people with advanced lung cancer will respond to immunotherapy, according to ...
Featured at this year’s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and ...
Bristol-Myers Squibb (NYSE:BMY | BMY Price Prediction) trades at $60.17 as of writing. The 24/7 Wall St. Price Target is ...
The team coordinated multiple design disciplines, authority approvals and specialist sub-consultants, with a clear focus on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results